Evaluation of Febrile Neutropenic Episodes of Childhood Malignancies

Mustafa Kemal Üniversitesi Tıp Dergisi

关键词: Çocukluk çağı;    febril nötropeni;    kanser;    lösemi;    Childhood;    febrile neutropenia;    cancer;    leukemia;   

DOI  :  10.17944/mkutfd.489213

来源: DOAJ

【 摘 要 】

Introduction:The most important side effect of therapeutics given for cancer treatment is febrile neutropenia. Neutropenia expected to be longer than seven days and severe neutropenia (absolute neutrophil count <100/mm3) especially in hematologic cancers and solid organ tumors that show bone marrow dissemination is accepted as a high-risk feature by American Infectious Disease Society. The emergent approach to a febrile neutropenia attack is to give intravascular antibiotherapy within the shortest time possible. We aimed to evaluate the febrile neutropenia attacks of pediatric cancer patients in a tertiary referral hospital during a 27-month period.Methods:Febrile neutropenia attacks of cases treated between January 2012 and March 2014 were investigated retrospectively from the patient files. Febrile neutropenia was defined as absolute neutrophil count below 500/mm3 or between 500-1000/ mm3 but expected to fall below 500/mm3 within 48 hours in the presence of fever of 38,50C with single axillary measurement or above 380C for one hour or two measurements above 380C within 4 hours.Results:One hundred thirty-one febrile neutropenia attacks of 48 patients were investigated retrospectively. Fever was managed within 24 hours in 69% patients. Peripheral and catheter-drawn blood cultures showed bacterial growth in 36% of the attacks, 64% of these growths being gram negative bacteria. Empirical treatment with piperacilin-taxobactam was observed to be efficient in 32% of the attacks. As a supportive treatment, cases received G-CSF in 19% of the attacks.Conclusion:In order to, minimize morbidity and mortality of febrile neutropenia, wide spectrum antibiotics must be given intravenously within the shortest time possible in pediatric cancers.

【 授权许可】

Unknown